Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 3/20 | 0.33 |
| ▸ | DRD2 | P14416 | 3/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | HTR7 | P34969 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.31 |
| ▸ | XIAP | P98170 | 4/20 | 0.31 |
| ▸ | BIRC3 | Q13489 | 3/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | TNF | P01375 | 4/20 | 0.31 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2437938 | 0.89 | BIRC3 (0.42) | XIAPBIRC3TNF | |
| SCHEMBL2442469 | 0.86 | AAK1 (0.34) | CCR2DRD2HTR2AHTR7KCNH2 | |
| SCHEMBL2446124 | 0.84 | CTSL (0.42) | CTSLCACNA1B | |
| SCHEMBL2442067 | 0.83 | DRD2 (0.34) | SCN9ACCR2DRD2HTR2AHTR7 | |
| SCHEMBL12299628 | 0.83 | DRD2 (0.34) | SCN9ACCR2DRD2HTR2AHTR7 | |
| SCHEMBL13448815 | 0.82 | HTR2A (0.35) | DRD2HTR2AHTR7KCNH2CTSL | |
| SCHEMBL2443816 | 0.80 | XIAP (0.42) | XIAPBIRC3TNF | |
| SCHEMBL2438546 | 0.77 | HSD11B1 (0.36) | CCR2DRD2HTR2AHTR7KCNH2 | |
| SCHEMBL12329668 | 0.77 | HSD11B1 (0.36) | CCR2DRD2HTR2AHTR7KCNH2 | |
| SCHEMBL2445839 | 0.77 | XIAP (0.32) | DRD2HTR2AHTR7KCNH2XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237517-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP. | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237517-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | SCN9A 2036/4885CCR2 3192/4885DRD2 4857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.